FDA, CDC call for pause of chikungunya shot rollout in older adults
The FDA and the Centers for Disease Control and Prevention are recommending a pause in the use of Valneva's chikungunya vaccine in older adults as investigations into serious adverse event reports play out on both sides of the Atlantic.
The FDA and the Centers for Disease Control and Prevention are recommending a pause in the use of Valneva's chikungunya vaccine in older adults as investigations into serious adverse event reports play out on both sides of the Atlantic.
